MY178120A - Anti sez6 antibodies and methods of use - Google Patents
Anti sez6 antibodies and methods of useInfo
- Publication number
- MY178120A MY178120A MYPI2014002467A MYPI2014002467A MY178120A MY 178120 A MY178120 A MY 178120A MY PI2014002467 A MYPI2014002467 A MY PI2014002467A MY PI2014002467 A MYPI2014002467 A MY PI2014002467A MY 178120 A MY178120 A MY 178120A
- Authority
- MY
- Malaysia
- Prior art keywords
- methods
- sez6 antibodies
- anti sez6
- antibodies
- modulators
- Prior art date
Links
- 230000002062 proliferating effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261603203P | 2012-02-24 | 2012-02-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY178120A true MY178120A (en) | 2020-10-05 |
Family
ID=47790548
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2014002467A MY178120A (en) | 2012-02-24 | 2013-02-22 | Anti sez6 antibodies and methods of use |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US9676850B2 (enExample) |
| EP (2) | EP3539985A1 (enExample) |
| JP (2) | JP6401060B2 (enExample) |
| KR (1) | KR102099073B1 (enExample) |
| CN (2) | CN104334580B (enExample) |
| AU (3) | AU2013203506B2 (enExample) |
| CA (1) | CA2865415C (enExample) |
| CL (2) | CL2014002237A1 (enExample) |
| CO (1) | CO7151485A2 (enExample) |
| ES (1) | ES2741936T3 (enExample) |
| IL (1) | IL234208B (enExample) |
| MX (2) | MX373141B (enExample) |
| MY (1) | MY178120A (enExample) |
| NZ (1) | NZ631197A (enExample) |
| PE (1) | PE20150091A1 (enExample) |
| PH (2) | PH12020500604A1 (enExample) |
| RU (1) | RU2691698C2 (enExample) |
| SG (2) | SG11201405130UA (enExample) |
| WO (1) | WO2013126810A1 (enExample) |
| ZA (1) | ZA201406967B (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102099073B1 (ko) * | 2012-02-24 | 2020-04-10 | 애브비 스템센트알엑스 엘엘씨 | 항 ｓｅｚ6 항체들 및 사용 방법 |
| US11531028B2 (en) * | 2013-05-10 | 2022-12-20 | Nordic Bioscience A/S | Collagen type X alpha-1 assay |
| CA2922529A1 (en) * | 2013-08-28 | 2015-03-05 | Stemcentrx, Inc. | Novel sez6 modulators and methods of use |
| JP2016531915A (ja) | 2013-08-28 | 2016-10-13 | ステムセントリックス， インコーポレイテッド | 部位特異的抗体コンジュゲーション方法および組成物 |
| PE20161413A1 (es) | 2013-11-04 | 2017-01-10 | Stemcentrx Inc | Conjugados de anticuerpo anti-efna4-farmaco |
| SG11201604503XA (en) * | 2013-12-03 | 2016-07-28 | Agency Science Tech & Res | Cytotoxic antibody |
| PT3101131T (pt) * | 2014-01-29 | 2020-11-05 | Univ Kumamoto Nat Univ Corp | Anticorpo antitranstirretina humanizado |
| PT3101132T (pt) * | 2014-01-29 | 2021-12-31 | Km Biologics Co Ltd | Anticorpo humano anti-transtirretina |
| WO2015127407A1 (en) | 2014-02-21 | 2015-08-27 | Stemcentrx, Inc. | Anti-dll3 antibodies and drug conjugates for use in melanoma |
| WO2015200073A1 (en) * | 2014-06-23 | 2015-12-30 | Bionomics, Inc. | Antibodies that bind lgr4 |
| TW201617368A (zh) * | 2014-09-05 | 2016-05-16 | 史坦森特瑞斯公司 | 新穎抗ｍｆｉ２抗體及使用方法 |
| WO2016057683A2 (en) | 2014-10-07 | 2016-04-14 | Ann And Robert H. Lurie Children's Hospital Of Chicago | Novel anti-nodal antibodies and methods of using same |
| MX2018002166A (es) * | 2015-08-20 | 2018-09-12 | Abbvie Stemcentrx Llc | Conjugados anticuerpo anti-dll3-farmaco y metodos de uso. |
| CN108369269B (zh) | 2015-10-06 | 2022-06-14 | 日本先锋公司 | 光控制装置、光控制方法和程序 |
| WO2017087547A1 (en) * | 2015-11-17 | 2017-05-26 | Oncomed Pharmaceuticals, Inc. | Pd-l1-binding agents and uses thereof |
| JP7109382B2 (ja) | 2016-03-04 | 2022-07-29 | ジェイエヌ バイオサイエンシーズ エルエルシー | Ｔｉｇｉｔに対する抗体 |
| EP3525814A4 (en) | 2016-10-14 | 2020-09-23 | Nima Labs, Inc. | ANTI-GLIADINE ANTIBODY |
| AU2017344411A1 (en) * | 2016-10-19 | 2019-05-09 | Novelogics Biotechnology, Inc. | Antibodies to MICA and MICB proteins |
| WO2018107116A1 (en) * | 2016-12-09 | 2018-06-14 | Abbvie Stemcentrx Llc | Methods of reducing toxicity of antibody drug conjugates, and compositions produced thereby |
| US11634486B2 (en) * | 2016-12-23 | 2023-04-25 | Bluefin Biomedicine, Inc. | Anti-SEZ6L2 antibodies and antibody drug conjugates |
| EP3424527A1 (de) | 2017-07-07 | 2019-01-09 | AVA Lifescience GmbH | Diagnostisches verfahren |
| JP7278623B2 (ja) * | 2018-04-13 | 2023-05-22 | ディンフー バイオターゲット カンパニー リミテッド | 抗ｃｄ２７抗体およびその使用 |
| MA51453A (fr) * | 2018-05-30 | 2020-09-23 | Abbvie Stemcentrx Llc | Conjugués anticorps anti-sez6-médicaments et procédés d'utilisation |
| US12091453B2 (en) * | 2018-07-11 | 2024-09-17 | Hedgehog, Inc. | Epitope specific to SMO protein, antibody recognizing same, and composition comprising same |
| KR20250172902A (ko) | 2018-07-31 | 2025-12-09 | 다이이찌 산쿄 가부시키가이샤 | 항체-약물 콘주게이트 투여에 의한 전이성 뇌종양의 치료 |
| US12162944B2 (en) * | 2018-08-24 | 2024-12-10 | Jiangsu Hengrui Medicine Co., Ltd. | Human IL-4R binding antibody, antigen binding fragment thereof, and medical use thereof |
| PE20231078A1 (es) | 2020-06-02 | 2023-07-17 | Arcus Biosciences Inc | Anticuerpos anti-tigit |
| CN114106176B (zh) * | 2020-09-01 | 2024-04-09 | 深圳市菲鹏生物治疗股份有限公司 | Cd22抗体及其应用 |
| WO2022051223A1 (en) * | 2020-09-02 | 2022-03-10 | The Feinstein Institutes For Medical Research | Use of sars-cov-2 receptor binding motif (rbm)-reactive monoclonal antibodies to treat covid-19 |
| CN116761635A (zh) | 2020-11-24 | 2023-09-15 | 诺华股份有限公司 | Bcl-xl抑制剂抗体药物缀合物及其使用方法 |
| CN114790241B (zh) * | 2021-01-26 | 2024-12-13 | 北京免疫方舟医药科技有限公司 | 抗tigit抗体及其应用 |
| CN113307875B (zh) * | 2021-06-10 | 2022-09-02 | 福州迈新生物技术开发有限公司 | 抗TCRβF1蛋白单克隆抗体及其细胞株、制备方法和应用 |
| WO2023019174A2 (en) * | 2021-08-11 | 2023-02-16 | Apollos Diagnostics, Llc | Antibodies to sars-cov-2 |
| WO2023223097A1 (en) | 2022-05-20 | 2023-11-23 | Novartis Ag | Antibody drug conjugates |
| KR20250027285A (ko) | 2022-05-20 | 2025-02-25 | 노파르티스 아게 | 항신생물 화합물의 항체-약물 접합체 및 그의 사용 방법 |
| CN115975036B (zh) * | 2022-08-18 | 2023-06-09 | 北京诺赛国际医学研究院 | 包含干细胞的药物组合物及其治疗癌症的用途 |
| AU2024270504A1 (en) * | 2023-05-08 | 2025-11-27 | Changzhou Hansoh Pharmaceutical Co., Ltd. | Antibody or antigen-binding fragment thereof, antibody-drug conjugate, and use thereof |
| CN117736331B (zh) * | 2024-02-04 | 2024-05-07 | 南昌大学第一附属医院 | 一种特异性结合psma胞外段的单克隆抗体及其应用 |
| WO2025167503A1 (en) * | 2024-02-05 | 2025-08-14 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Anti-sez6/b7h3 antibodies and uses thereof |
| CN120904329A (zh) * | 2024-10-18 | 2025-11-07 | 北京大学第一医院(北京大学第一临床医学院) | 一种抗sez6纳米抗体或抗原结合片段与应用 |
| CN120365421B (zh) * | 2025-04-24 | 2025-11-04 | 成都古格尔生物技术有限公司 | 一种特异性抗sez6靶点的全人源抗体及其制备方法和应用 |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| US5336603A (en) | 1987-10-02 | 1994-08-09 | Genentech, Inc. | CD4 adheson variants |
| KR900005995A (ko) | 1988-10-31 | 1990-05-07 | 우메모또 요시마사 | 변형 인터류킨-2 및 그의 제조방법 |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5112946A (en) | 1989-07-06 | 1992-05-12 | Repligen Corporation | Modified pf4 compositions and methods of use |
| WO1991006570A1 (en) | 1989-10-25 | 1991-05-16 | The University Of Melbourne | HYBRID Fc RECEPTOR MOLECULES |
| US5349053A (en) | 1990-06-01 | 1994-09-20 | Protein Design Labs, Inc. | Chimeric ligand/immunoglobulin molecules and their uses |
| WO1992010591A1 (en) | 1990-12-14 | 1992-06-25 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
| US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
| US5447851B1 (en) | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
| MD1367C2 (ro) | 1992-11-13 | 2000-11-30 | Idec Pharmaceuticals Corporation | Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom. |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| JPH10503371A (ja) | 1994-07-29 | 1998-03-31 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | 新規化合物 |
| WO1998052976A1 (en) | 1997-05-21 | 1998-11-26 | Biovation Limited | Method for the production of non-immunogenic proteins |
| ES2375931T3 (es) | 1997-12-05 | 2012-03-07 | The Scripps Research Institute | Humanización de anticuerpo murino. |
| ES2244210T3 (es) | 1998-08-27 | 2005-12-01 | Spirogen Limited | Pirrolobenzodiazepinas. |
| CA2342967A1 (en) | 1998-12-08 | 2000-06-15 | Biovation Limited | Modifying protein immunogenicity |
| US20040067490A1 (en) * | 2001-09-07 | 2004-04-08 | Mei Zhong | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| EP1290026A2 (en) * | 2000-04-28 | 2003-03-12 | Eli Lilly And Company | Human sez6 nucleic acids and polypeptides |
| US7608704B2 (en) | 2000-11-08 | 2009-10-27 | Incyte Corporation | Secreted proteins |
| US6362331B1 (en) | 2001-03-30 | 2002-03-26 | Council Of Scientific And Industrial Research | Process for the preparation of antitumor agents |
| US20030211991A1 (en) * | 2001-04-17 | 2003-11-13 | Su Eric Wen | Human sez6 nucleic acids and polypeptides |
| CN1343774A (zh) | 2001-05-28 | 2002-04-10 | 复旦大学 | 一种癫痫相关蛋白编码序列,其编码的多肽、制法及用途 |
| EP1487492A4 (en) | 2002-03-04 | 2008-10-01 | Medimmune Inc | PREVENTION OR TREATMENT OF CANCER WITH INTEGRIN ALPHAVBETA3 ANTAGONISTS IN COMBINATION WITH OTHER MEDICINES |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| GB0226593D0 (en) | 2002-11-14 | 2002-12-24 | Consultants Ltd | Compounds |
| WO2004072266A2 (en) | 2003-02-13 | 2004-08-26 | Kalobios Inc. | Antibody affinity engineering by serial epitope-guided complementarity replacement |
| WO2004101756A2 (en) | 2003-05-09 | 2004-11-25 | Diadexus, Inc. | Ovr110 antibody compositions and methods of use |
| GB0321295D0 (en) | 2003-09-11 | 2003-10-15 | Spirogen Ltd | Synthesis of protected pyrrolobenzodiazepines |
| PL2489364T3 (pl) | 2003-11-06 | 2015-06-30 | Seattle Genetics Inc | Związki monometylowaliny zdolne do sprzęgania do przeciwciał |
| GB0404577D0 (en) | 2004-03-01 | 2004-04-07 | Spirogen Ltd | Pyrrolobenzodiazepines |
| PT2270010E (pt) | 2004-03-01 | 2012-03-12 | Spirogen Ltd | Derivados de 11-hidroxi-5h-pirrolo[2,1-c][1,4]benzodiazepin- 5-ona como intermediários chave para a preparação de pirrolobenzodiazepinas substituídas em c2 |
| US7189710B2 (en) | 2004-03-30 | 2007-03-13 | Council Of Scientific And Industrial Research | C2-fluoro pyrrolo [2,1−c][1,4]benzodiazepine dimers |
| FR2869231B1 (fr) | 2004-04-27 | 2008-03-14 | Sod Conseils Rech Applic | Composition therapeutique contenant au moins un derive de la pyrrolobenzodiazepine et la fludarabine |
| BRPI0516284A (pt) | 2004-09-23 | 2008-09-02 | Genentech Inc | anticorpo construìdo com cisteìna, método de selecionar anticorpos, compostos conjugados de droga-anticorpo, composição farmacêutica, método para matar ou inibir a proliferação de células de tumor, métodos de inibir a proliferação celular e o crescimento de células de tumor, artigo manufaturado e método para produzir um composto |
| US20070123448A1 (en) | 2005-11-23 | 2007-05-31 | The Hospital For Sick Children | Novel chemical entities affecting neuroblastoma tumor-initiating cells |
| ATE527262T1 (de) | 2006-01-25 | 2011-10-15 | Sanofi Sa | Neue tomaymycin derivate enhaltende zytotoxische mittel |
| WO2007145901A1 (en) | 2006-06-06 | 2007-12-21 | University Of Tennessee Research Foundation | Compositions enriched in neoplastic stem cells and methods comprising same |
| NZ572561A (en) | 2006-06-07 | 2012-05-25 | Bioalliance Cv | Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same |
| US7763242B2 (en) | 2006-09-07 | 2010-07-27 | Scott and White Memorial Hospital | Methods for treating myelodysplastic syndrome with a human interleukin-3-diphtheria toxin conjugate |
| EP2109668A4 (en) | 2007-01-22 | 2011-10-05 | Macrogenics West Inc | HUMAN CANCER STEM CELLS |
| SI2170959T1 (sl) * | 2007-06-18 | 2014-04-30 | Merck Sharp & Dohme B.V. | Protitelesa proti receptorjem pd-1 za humano programirano smrt |
| WO2009012357A2 (en) | 2007-07-17 | 2009-01-22 | The General Hospital Corporation | Methods to identify and enrich for populations of ovarian cancer stem cells and somatic ovarian stem cells and uses thereof |
| EP2022848A1 (en) | 2007-08-10 | 2009-02-11 | Hubrecht Institut | A method for identifying, expanding, and removing adult stem cells and cancer stem cells |
| US20090155255A1 (en) | 2007-09-27 | 2009-06-18 | Biogen Idec Ma Inc. | Cd23 binding molecules and methods of use thereof |
| ES2613963T3 (es) | 2008-01-18 | 2017-05-29 | Medimmune, Llc | Anticuerpos manipulados con cisteína para conjugación específica de sitio |
| EP2282769A4 (en) | 2008-04-29 | 2012-04-25 | Abbott Lab | DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES |
| US20100162416A1 (en) | 2008-09-29 | 2010-06-24 | Stemlifeline, Inc. | Multi-stage stem cell carcinogenesis |
| WO2010081171A2 (en) | 2009-01-12 | 2010-07-15 | Cyntellect, Inc. | Laser mediated sectioning and transfer of cell colonies |
| US20110020221A1 (en) | 2009-04-09 | 2011-01-27 | The Johns Hopkins University | Cancer stem cell expression patterns and compounds to target cancer stem cells |
| CN102612524A (zh) | 2009-09-01 | 2012-07-25 | 雅培制药有限公司 | 双重可变结构域免疫球蛋白及其用途 |
| SI2544719T1 (sl) * | 2010-03-12 | 2019-11-29 | Debiopharm Int Sa | CD37-povezovalne molekule in njihovi imunokonjugati |
| EP2558475A1 (en) | 2010-04-15 | 2013-02-20 | Spirogen Sàrl | Pyrrolobenzodiazepines used to treat proliferative diseases |
| MX2012011900A (es) | 2010-04-15 | 2013-03-21 | Seattle Genetics Inc | Conjugados de pirrolobenzodiazepina diana. |
| GB201006340D0 (en) | 2010-04-15 | 2010-06-02 | Spirogen Ltd | Synthesis method and intermediates |
| NZ602241A (en) | 2010-04-15 | 2015-03-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| WO2012012801A2 (en) | 2010-07-23 | 2012-01-26 | The Johns Hopkins University | Device for capture, enumeration, and profiling of circulating tumor cells |
| WO2012019060A1 (en) * | 2010-08-05 | 2012-02-09 | Joslin Diabetes Center, Inc. | Predicting and treating diabetic complications |
| EP2611463A2 (en) | 2010-09-03 | 2013-07-10 | Stem Centrx, Inc. | Identification and enrichment of cell subpopulations |
| US20130061340A1 (en) | 2011-09-02 | 2013-03-07 | Stem Centrx, Inc. | Identification and Enrichment of Cell Subpopulations |
| US9778264B2 (en) | 2010-09-03 | 2017-10-03 | Abbvie Stemcentrx Llc | Identification and enrichment of cell subpopulations |
| WO2013119964A2 (en) | 2012-02-08 | 2013-08-15 | Stem Centrx, Inc. | Identification and enrichment of cell subpopulations |
| US20130061342A1 (en) | 2011-09-02 | 2013-03-07 | Stem Centrx, Inc. | Identification and Enrichment of Cell Subpopulations |
| HUE038908T2 (hu) | 2010-09-29 | 2018-12-28 | Agensys Inc | 191P4D12 proteinekhez kötõdõ antitest-gyógyszerkonjugátumok (ADC) |
| KR102099073B1 (ko) * | 2012-02-24 | 2020-04-10 | 애브비 스템센트알엑스 엘엘씨 | 항 ｓｅｚ6 항체들 및 사용 방법 |
| CA2922529A1 (en) | 2013-08-28 | 2015-03-05 | Stemcentrx, Inc. | Novel sez6 modulators and methods of use |
| JP2016531915A (ja) * | 2013-08-28 | 2016-10-13 | ステムセントリックス， インコーポレイテッド | 部位特異的抗体コンジュゲーション方法および組成物 |
| WO2016064749A2 (en) | 2014-10-20 | 2016-04-28 | Igenica Biotherapeutics, Inc. | Novel antibody-drug conjugates and related compounds, compositions, and methods of use |
| MA41645A (fr) * | 2015-03-04 | 2018-01-09 | Abbvie Stemcentrx Llc | Anticorps issus de génie génétique spécifiques au site et méthodes d'utilisation |
| US11634486B2 (en) | 2016-12-23 | 2023-04-25 | Bluefin Biomedicine, Inc. | Anti-SEZ6L2 antibodies and antibody drug conjugates |
-
2013
- 2013-02-22 KR KR1020147026846A patent/KR102099073B1/ko not_active Expired - Fee Related
- 2013-02-22 AU AU2013203506A patent/AU2013203506B2/en not_active Ceased
- 2013-02-22 ES ES13707529T patent/ES2741936T3/es active Active
- 2013-02-22 EP EP19154773.6A patent/EP3539985A1/en not_active Withdrawn
- 2013-02-22 SG SG11201405130UA patent/SG11201405130UA/en unknown
- 2013-02-22 EP EP13707529.7A patent/EP2817339B1/en active Active
- 2013-02-22 CN CN201380010534.6A patent/CN104334580B/zh not_active Expired - Fee Related
- 2013-02-22 PH PH1/2020/500604A patent/PH12020500604A1/en unknown
- 2013-02-22 WO PCT/US2013/027476 patent/WO2013126810A1/en not_active Ceased
- 2013-02-22 PE PE2014001301A patent/PE20150091A1/es active IP Right Grant
- 2013-02-22 CA CA2865415A patent/CA2865415C/en active Active
- 2013-02-22 CN CN201810153825.5A patent/CN108383909B/zh not_active Expired - Fee Related
- 2013-02-22 NZ NZ631197A patent/NZ631197A/en not_active IP Right Cessation
- 2013-02-22 MX MX2014010094A patent/MX373141B/es active IP Right Grant
- 2013-02-22 JP JP2014558901A patent/JP6401060B2/ja not_active Expired - Fee Related
- 2013-02-22 MY MYPI2014002467A patent/MY178120A/en unknown
- 2013-02-22 SG SG10201801444WA patent/SG10201801444WA/en unknown
- 2013-02-22 US US14/380,665 patent/US9676850B2/en active Active
- 2013-02-22 RU RU2014138420A patent/RU2691698C2/ru active
-
2014
- 2014-08-19 IL IL234208A patent/IL234208B/en active IP Right Grant
- 2014-08-21 MX MX2020003713A patent/MX2020003713A/es unknown
- 2014-08-22 CL CL2014002237A patent/CL2014002237A1/es unknown
- 2014-08-26 PH PH12014501914A patent/PH12014501914B1/en unknown
- 2014-09-23 CO CO14210871A patent/CO7151485A2/es unknown
- 2014-09-23 ZA ZA2014/06967A patent/ZA201406967B/en unknown
-
2016
- 2016-09-07 AU AU2016225828A patent/AU2016225828B2/en not_active Ceased
-
2017
- 2017-06-05 US US15/614,548 patent/US10533051B2/en not_active Expired - Fee Related
- 2017-11-08 CL CL2017002823A patent/CL2017002823A1/es unknown
-
2018
- 2018-03-20 JP JP2018052506A patent/JP2018127469A/ja active Pending
- 2018-08-31 AU AU2018223053A patent/AU2018223053B2/en not_active Expired - Fee Related
-
2019
- 2019-12-12 US US16/712,324 patent/US20200181256A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12014501914A1 (en) | Anti sez6 antibodies and methods of use | |
| MX2018010548A (es) | Moduladores de ligando de tipo delta 3 (dll3) y metodos de uso. | |
| PH12018500452A1 (en) | Novel modulators and methods of use | |
| MX2016002574A (es) | Nuevos moduladores del homologo 6 (sez6) y metodos de uso. | |
| WO2013119960A3 (en) | Anti-cd324 monoclonal antibodies and uses thereof | |
| PH12017501139A1 (en) | Novel modulators and methods of use | |
| PH12015501846A1 (en) | Novel antibody conjugates and uses thereof | |
| PH12016500781A1 (en) | Novel anti-claudin antibodies and methods of use | |
| PH12016501109A1 (en) | Novel anti-dpep3 antibodies and methods of use | |
| PH12013500379A1 (en) | Notum protein modulators and methods of use | |
| WO2012031273A3 (en) | Novel modulators and methods of use | |
| EP4450130A3 (en) | Formulations of enzalutamide | |
| PH12017500825A1 (en) | Anti-cldn chimeric antigen receptors and methods of use | |
| EA201491947A1 (ru) | Антитела и иммуноконъюгаты к ly6e и способы применения | |
| PH12018501153A1 (en) | Novel anti-claudin antibodies and methods of use | |
| MX2016004540A (es) | Tiazolopirimidinonas como moduladores de la actividad de receptores de n-metil-d-aspartato (nmda). | |
| EP3549582A3 (en) | Novel capsazepine analogs for the treatment of cancer and other proliferative diseases | |
| HK1226641A1 (en) | Novel sez6 modulators and methods of use |